LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/LDR Reaches Major Milestones
Spine

LDR Reaches Major Milestones

May 11, 2015 1 min read Premium comments

Advertisement

LDR Reaches Major Milestones
VerteBRIDGE / Source: LDR Holding Corporation
Secondary

LDR Holding Corporation is celebrating two major recent milestones. The company indicates that it has reached 80, 000 implantations of its exclusive VerteBRIDGE plating technology and 30, 000 implantations of its exclusive Mobi-C Cervical Disc replacement technology worldwide.

LDR President and CEO Christophe Lavigne told OTW, “It is very rewarding to see continued, positive and global growth in our two, primary platform technologies. We are very pleased to communicate on the latest implantation numbers, and as we look toward the future, LDR will remain focused on offering a portfolio of innovative and highly differentiated products.”

VerteBRIDGE was introduced in France in 2007 and debuted in the U.S. a year later. They are equipped with integrated, zero-profile, in-line plating technology adapted for use in anterior cervical, anterior lumbar, oblique lumbar, and lateral lumbar applications.

A company representative told OTW, “In addition, LDR’s exclusive Mobi-C Cervical Disc, the only FDA approved disc for both one and two-level use, is a mobile-bearing prosthesis specifically designed as a bone-sparing, cervical intervertebral disc replacement. LDR believes that Mobi-C offers a simplified surgical technique as compared to other, commercially available devices. Additionally, Mobi-C demonstrated superiority to anterior cervical discectomy and fusion in the two-level FDA study in overall trial success at 24 months.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy